{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:47:45Z","timestamp":1791564465950,"version":"4.3.4"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010564","name":"Deutsche Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IrAE showed comparable frequencies in stage IV (198\/894 or 22%) <jats:italic>vs.<\/jats:italic> III (14\/45 or 31%, p = 0.15), after anti-PD-(L)1 monotherapy <jats:italic>vs.<\/jats:italic> chemoimmunotherapy (139\/483 <jats:italic>vs.<\/jats:italic> 58\/213, p = 0.75), and across treatment lines. In stage IV, irAE occurred after 3.1 months in median, affected multiple organs (median 2) in 27\/894 patients and were associated with PD-L1 positivity (25 <jats:italic>vs.<\/jats:italic> 14%, p = 0.003), lower neutrophil-to-lymphocyte ratios (29 <jats:italic>vs.<\/jats:italic> 17%, p &amp;lt; 0.001 for NLR dichotomized at 5), better ECOG status (26 <jats:italic>vs.<\/jats:italic> 18% for 0 <jats:italic>vs.<\/jats:italic> 1, p = 0.004), but not related to age, sex, smoking and palliative radiotherapy. Two hundred thirty two irAEs occurred mostly in endocrine glands (4.9%), lungs (4.4%), the musculoskeletal system (4.2%), colon (4.1%), liver (3.7%), and skin (2.6%), while pneumonitis was most frequent with durvalumab following definitive chemoradiation (16% or 7\/45, p &amp;lt; 0.01). IrAE severity was grade 1 in 11%, 2 in 41%, 3 in 36%, and 4 in 11% events, while two were lethal (&amp;lt;1%, myocarditis and pneumonitis). Therapy was suspended in 72%, while steroids were initiated in 66% and complemented by other immunosuppressants in 6%, with longest treatment duration for rheumatic events (mean &amp;gt;3 months), and average cumulative prednisone doses &amp;gt;700 mg for all organs, except for skin. Patients developing irAE had longer progression-free (PFS) and overall survival (OS) in multivariable 12\/14-week landmark analyses including ECOG status, treatment line, treatment type, PD-L1 TPS, and NLR (median PFS 17 <jats:italic>vs.<\/jats:italic> 10 months, HR = 0.68, p = 0.009; median OS 37 <jats:italic>vs.<\/jats:italic> 15 months, HR = 0.40, p &amp;lt; 0.001), regardless of grade. OS was longest with skin (95% at 2 years) and shortest with pneumonitis, hepatitis, neurologic, and cardiologic irAE (38, 37, 28, and 0% at 2 years, p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Approximately one-fourth of immunotherapy-treated NSCLC patients develop irAEs, most of which necessitate treatment suspension and steroids. Despite more frequent occurrence with PD-L1 positive tumors, lower NLR, and better ECOG PS, irAEs are independently associated with longer survival, especially when affecting the skin. Lethality is below 1%.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.703893","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T06:03:36Z","timestamp":1624946616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Lea","family":"Daniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Elshiaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kuon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Volckmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Lusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonore","family":"Diekmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Liersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Faehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000510385","article-title":"Immune Modulation in Lung Cancer: Current Concepts and Future Strategies","volume":"99","author":"Gaissmaier","year":"2020","journal-title":"Respiration"},{"key":"B3","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B4","unstructured":"PlanchardD\n            PopatS\n            KerrK\n            NovelloS\n            SmitEF\n            Faivre-FinnC\n          Esmo Clinical Practice Living Guidelines - Metastatic non-Small-Cell Lung Cancer2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"JCO.21.00174","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50%","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association Between Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non\u2013small-cell Lung Cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B7","volume-title":"Common Terminology Criteria for Adverse Events (Ctcae) Version 5.0","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thor Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32133","article-title":"Combined Targeted DNA and RNA Sequencing of Advanced NSCLC in Routine Molecular Diagnostics: Analysis of the First 3,000 Heidelberg Cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment Neutrophil-to-Lymphocyte Ratio and Mutational Burden as Biomarkers of Tumor Response to Immune Checkpoint Inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2092-x","article-title":"Post-Treatment Neutrophil-to-Lymphocyte Ratio at Week 6 Is Prognostic in Patients With Advanced Non-Small Cell Lung Cancers Treated With anti-PD-1 Antibody","volume":"67","author":"Suh","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1158\/1538-7445.Sabcs17-p3-17-03","article-title":"Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer Using Electronic Health Record With Proper Quality Control Versus Conventional PFS From a Phase 3 Trial","volume":"78","author":"Bartlett","year":"2018","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1581P","DOI":"10.1093\/annonc\/mdz260.103","article-title":"Comparison of Real-World Response Rate (rwRR) to RECIST-based Response Rate in Patients With Advanced Non-Small Cell Lung Cancer (Ansclc)","volume":"30","author":"Ma","year":"2019","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e000529","DOI":"10.1136\/esmoopen-2019-000529","article-title":"How I Treat Cancer: Treatment of Rheumatological Side Effects of Immunotherapy","volume":"4","author":"Benesova","year":"2019","journal-title":"ESMO Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of Arthralgia Induced by PD-1 Antibody Treatment in Patients With Metastasized Cutaneous Malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2284","article-title":"Lba51 KEYNOTE-024 5-Year OS Update: First-Line (1L) Pembrolizumab (Pembro) vs Platinum-Based Chemotherapy (Chemo) in Patients (Pts) With Metastatic NSCLC and PD-L1 Tumour Proportion Score (TPS) \u226550%","volume":"31","author":"Brahmer","year":"2020","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.486","article-title":"Oa14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017\/057: Nivolumab vs Docetaxel in Previously Treated Nsclc","volume":"14","author":"Gettinger","year":"2019","journal-title":"J Thor Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01222-w","article-title":"Immune Checkpoint Inhibition in Non-metastatic non-Small Cell Lung Cancer: Chance for Cure","volume":"79","author":"Heigener","year":"2019","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-Related Adverse Events With Immune Checkpoint Inhibitors in Thoracic Malignancies: Focusing on Non-Small Cell Lung Cancer Patients","volume":"10","author":"Remon","year":"2018","journal-title":"J Thor Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.08.09","article-title":"The Association of PD-L1 Expression With the Efficacy of Anti- PD-1\/PD-L1 Immunotherapy and Survival of Non-Small Cell Lung Cancer Patients: A Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Xu","year":"2019","journal-title":"Transl Lung Canc Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00654","article-title":"Pretreatment Neutrophil-to-Lymphocyte Ratio (Nlr) May Predict the Outcomes of Advanced Non-Small-Cell Lung Cancer (Nsclc) Patients Treated With Immune Checkpoint Inhibitors (Icis)","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG Performance Status \u22652 as a Prognostic Factor in Patients With Advanced Non Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors-a Systematic Review and Meta-Analysis of Real World Data","volume":"145","author":"Dall\u2019Olio","year":"2020","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e21651","article-title":"Poor Performance Status and Front-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients With PD-L1>50%","volume":"38","author":"Addeo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/cancers12041046","article-title":"Oligoprogressive Non-Small-Cell Lung Cancer Under Treatment With PD-(L)1 Inhibitors","volume":"12","author":"Rheinheimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.21037\/atm-20-1513","article-title":"Plasma Cytokines interleukin-18 and C-X-C Motif Chemokine Ligand 10 Are Indicative of the Anti-Programmed Cell Death Protein-1 Treatment Response in Lung Cancer Patients","volume":"9","author":"Wang","year":"2021","journal-title":"Annal Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-a Comprehensive Review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.225","article-title":"Graft-Versus-Host Disease Versus Graft-Versus-Leukemia","volume":"2015","author":"Negrin","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.beha.2008.02.011","article-title":"Impact of Graft-Versus-Host Disease on Survival","volume":"21","author":"Pasquini","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1825","article-title":"Safety of Combined PD-1 Pathway Inhibition and Radiation Therapy for Non-Small-Cell Lung Cancer: A Multicentric Retrospective Study From the GFPC","volume":"7","author":"Lesueur","year":"2018","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2020.1783677","article-title":"Anti-Pd-1-Related Exacerbation of Interstitial Lung Disease in a Patient With Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature","volume":"38","author":"Gemmill JA","year":"2020","journal-title":"Cancer Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15171","article-title":"Pre-Existing Interstitial Lung Abnormalities Are Risk Factors for Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease in Non-NSCLC Cancers","volume":"38","author":"Shimoji","year":"2020","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline Serum TSH Levels Predict the Absence of Thyroid Dysfunction in Cancer Patients Treated With Immunotherapy","author":"Brilli","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800","article-title":"Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are Immune-Related Adverse Events Associated With the Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer? A Systematic Review and Meta-Analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-Related Adverse Events Correlate With Improved Survival in Patients Undergoing Anti-PD1 Immunotherapy for Metastatic Melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of Thyroid Dysfunction Is Associated With Clinical Response to PD-1 Blockade Treatment in Patients With Advanced Non-Small Cell Lung Cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated With Programmed Cell Death 1 Inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Onoclogist"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1615636","article-title":"Efficacy and Safety of Immune Checkpoint Inhibitors in a Danish Real Life non-Small Cell Lung Cancer Population: A Retrospective Cohort Study","volume":"58","author":"Bj\u00f8rnhart","year":"2019","journal-title":"Acta Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607531","article-title":"Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1\/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01728","article-title":"Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors","volume":"38","author":"Dall\u2019Olio","year":"2019","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis","volume":"13","author":"Dall\u2019Olio","year":"2021","journal-title":"Immunotherapy"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","article-title":"Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study","volume":"11","author":"Morimoto","year":"2021","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations Between the Immune-Related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non\u2013Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7065","article-title":"Real-World Outcomes of Immune-Related Adverse Events in 2,125 Patients Managed With Immunotherapy: A United Kingdom Multicenter Series","volume":"38","author":"Olsson-Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be Learnt From Real-World Studies on Immune-Related Adverse Events With Checkpoint Inhibitors: A Clinical Perspective From Pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Targeted Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-008-0211-6","article-title":"Strategies for Minimizing Corticosteroid Toxicity: A Review","volume":"75","author":"Aulakh","year":"2008","journal-title":"Indian J Pediatr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of Infectious Complications in Patients Taking Glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz449.001","article-title":"Association of Systemic Corticosteroids With Overall Survival in Patients Receiving Cancer Immunotherapy for Advanced Melanoma, non-Small Cell Lung Cancer or Urothelial Cancer in Routine Clinical Practice","volume":"30","author":"Drakaki","year":"2019","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"xi16","DOI":"10.1093\/annonc\/mdz449","article-title":"Impact of Early Introduction of Steroid on Immune-Checkpoint Inhibitors (ICI) in Patients With Advanced non-Small Cell Lung Cancer Treated","volume":"30","author":"de Giglio","year":"2019","journal-title":"Ann Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and Treatment of Systemic Glucocorticoid Side Effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int J Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.018","article-title":"Incidence and Risk Factors for Corticosteroid-Induced Lipodystrophy: A Prospective Study","volume":"57","author":"Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1749-6632.2009.04981.x","article-title":"Effects of Glucocorticoids on Mood, Memory, and the Hippocampus. Treatment and Preventive Therapy","volume":"1179","author":"Brown","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric Adverse Effects of Corticosteroids","volume":"81","author":"Warrington","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200108","article-title":"The Epidemiology of Corticosteroid-Induced Osteoporosis: A Meta-Analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporosis Int"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(86)90077-9","article-title":"Corticosteroid-Induced Cataracts","volume":"31","author":"Urban","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01677","article-title":"Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-Pd-(L)1 Blockade Agents","volume":"10","author":"Riudavets","year":"2020","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.703893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T06:03:42Z","timestamp":1624946622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.703893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":69,"alternative-id":["10.3389\/fonc.2021.703893"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.703893","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"article-number":"703893"}}